✅ Nvidia's debt is less than one-third of its assets, indicating strong financial health.
📈 The company's free cash flow has been consistently growing.
💪 This financial stability supports further growth and shareholder returns.
🌍 The ETF includes many of the most important companies in the sector globally.
✅ Novo Nordisk and Eli Lilly represent approximately 12% of the total portfolio.
📉 It has a low expense ratio of around 0.25% annually.
⚖️ Diversification reduces the risk associated with the dependence on a single company.
✅ Novo Nordisk's Wegovy has FDA and EMA approval for obesity and overweight treatment.
📈 The company has shown sustained growth in profitability, with increasing EBITDA and positive earnings per share.
💰 It maintains a stable dividend history with a payout close to 50%, offering investors consistent returns.
🔴 A sharp 20% stock drop occurred due to the underperformance of its new-generation obesity drug, Caris Erma.
🚀 Eli Lilly's Monjaro shows promise in obesity treatment, with an average weight reduction of 26% in patients.
⚠️ The drug is still in phase three clinical trials for specific application in overweight reduction.
📈 Positive evolution of Monjaro has contributed to improved financial results for Eli Lilly.
💰 The company has an impressive history of dividend payments, increasing them consistently for 11 years.
🏛️ Donald Trump's re-election has led to more favorable crypto regulations, boosting institutional investment in Ethereum.
📈 The approval of Ethereum ETCs in Europe facilitates easier access for large investors.
🌐 Ethereum's strong ecosystem, driven by DeFi and NFTs, supports its leading position in the crypto market.
🛡️ ETCs offer a regulated and secure way to invest in Ethereum without the complexities of direct cryptocurrency management.
